{"id":"https://openalex.org/A5114545511","orcid":"https://orcid.org/0009-0006-7567-4861","observed_orcids":["https://orcid.org/0009-0006-7567-4861"],"display_name":"Omar Mahmood Al-Azzawi","raw_author_names":["OMAR Mahmood AL-AZZAWI","Omar AL-Azzawi","Omar Al-azzaw\u0131","Omar Al\u2011Azzawi","Omar Mahmood AL-AZZAWI","Omar Mahmood Al-Azzawi"],"full_name":"Omar Mahmood Al-Azzawi","works_count":9,"cited_by_count":7,"summary_stats":{"2yr_mean_citedness":0.7777777777777778,"h_index":2,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5114545511","orcid":"https://orcid.org/0009-0006-7567-4861","observed_orcids":["https://orcid.org/0009-0006-7567-4861"]},"affiliations":[{"institution":{"id":"https://openalex.org/I4210121333","ror":"https://ror.org/03081nz23","display_name":"Istinye University","country_code":"TR","type":"education","lineage":["https://openalex.org/I4210121333"]},"years":[2026,2025,2024]}],"last_known_institutions":[{"id":"https://openalex.org/I4210121333","ror":"https://ror.org/03081nz23","display_name":"Istinye University","country_code":"TR","type":"education","lineage":["https://openalex.org/I4210121333"]}],"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","count":3,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10066","display_name":"Gut microbiota and health","count":2,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10106","display_name":"Autism Spectrum Disorder Research","count":2,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10365","display_name":"Gastrointestinal motility and disorders","count":2,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","count":2,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"topic_share":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","value":1.18e-05,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10971","display_name":"Olfactory and Sensory Function Studies","value":1.02e-05,"subfield":{"id":"https://openalex.org/subfields/2809","display_name":"Sensory Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11368","display_name":"Long-Term Effects of COVID-19","value":8.2e-06,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","value":7.7e-06,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11967","display_name":"Electrolyte and hormonal disorders","value":7.7e-06,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"x_concepts":[{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.9621000289916992},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.7469000220298767},{"id":"197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","score":0.5787000060081482},{"id":"177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","score":0.38960000872612},{"id":"2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","score":0.3319999873638153}],"counts_by_year":[{"year":2024,"works_count":1,"oa_works_count":1,"cited_by_count":0},{"year":2025,"works_count":1,"oa_works_count":1,"cited_by_count":0},{"year":2026,"works_count":7,"oa_works_count":7,"cited_by_count":7}],"display_name_alternatives":["OMAR Mahmood AL-AZZAWI","Omar AL-Azzawi","Omar Al-azzaw\u0131","Omar Al\u2011Azzawi","Omar Mahmood AL-AZZAWI","Omar Mahmood Al-Azzawi"],"block_key":"o al-azzawi","works_api_url":"https://api.openalex.org/works?filter=author.id:A5114545511","awards_count":0,"awards_api_url":"https://api.openalex.org/awards?filter=investigators.author.id:A5114545511","updated_date":"2026-11-10T14:30:39","created_date":"2024-11-07T00:00:00"}